Form 8-K

8-K — BIOVIE INC.

Accession: 0001520138-26-000312

Filed: 2026-08-06

Period: 2026-08-06

CIK: 0001580149

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — bivi-20260806_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (bivi-20260806_8kex99z1.htm)

GRAPHIC (image_01.jpg)

GRAPHIC (image_02.jpg)

GRAPHIC (image_03.jpg)

GRAPHIC (image_04.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: bivi-20260806_8k.htm · Sequence: 1

false

0001580149

2026-08-06

0001580149

bivi:ClassCommonStockParValue0.0001PerShareMember

2026-08-06

0001580149

bivi:WarrantsToPurchaseClassCommonStock0.0001ParValuePerShareMember

2026-08-06

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August

6, 2026

BioVie Inc.

(Exact name of registrant as specified in its charter)

Nevada

001-39015

46-2510769

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS Employer Identification No.)

680 W Nye Lane, Suite 201

Carson City, NV

89703

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area

code: (775) 888-3162

Check the appropriate box below if the Form 8-K filing is intended to simultaneously

satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant

to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to

Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of

the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, Par Value $0.0001 Per Share

BIVI

The Nasdaq Stock Market, LLC

Warrants to purchase Class A Common Stock, $0.0001 par value per share

BIVIW

The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant is an

emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark

if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of

Item 7.01. Regulation FD Disclosure.

On August 6, 2026, BioVie Inc. (the

“Company”) issued a press release announcing results from the Company’s Phase 2 SUNRISE-PD trial evaluating its

drug candidate bezisterim in early-stage Parkinson’s disease. A copy of the press release is attached hereto as Exhibit 99.1 and

incorporated by reference herein.

The information in this Item 7.01,

including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and

shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act,

except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated August 6, 2026

104

Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange

Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioVie INC.

By:

/s/ Joanne Wendy Kim

Name:

Joanne Wendy Kim

Title:

Chief Financial Officer

Date: August 6, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: bivi-20260806_8kex99z1.htm · Sequence: 2

Exhibit 99.1

BioVie Announces Topline Results of Phase 2 SUNRISE-PD

Trial of Bezisterim in Early Parkinson’s Disease

Patients treated with bezisterim demonstrated statistically

significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS1 Parts

I, II, and III, as well as a composite endpoint comprising 15 clinically relevant measures.

Bezisterim treatment appeared to have a beneficial

impact on plasma biomarkers of neurodegeneration and reduced biomarkers of both neuro- and systemic-inflammation.

Bezisterim treatment appeared to have a broad, proteome-wide

impact, with 283 of 380 proteins shifting in the direction that has been shown to suggest slowing of disease progression.

Conference call scheduled for 4:15 p.m. on August

12, 2026, to discuss results.

CARSON CITY, Nev., August 6, 2026 – BioVie Inc. (NASDAQ: BIVI) (“BioVie”

or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases,

today announced results from the Company’s Phase 2 SUNRISE-PD trial evaluating its drug candidate bezisterim in early-stage Parkinson’s

disease (PD).

The SUNRISE-PD trial was a Phase 2, multicenter, randomized, double-blind,

placebo-controlled trial designed to establish proof-of-mechanism and proof-of-concept in patients with early-stage PD that had not previously

been treated with carbidopa/levodopa. Under the statistical analysis plan submitted to the U.S. Food and Drug Administration (FDA), the

study’s primary pharmacodynamic assessment focused on changes in a predefined panel of blood-based inflammatory markers of disease.

The study also evaluated motor and non-motor endpoints, clinician-rated outcomes, quality-of-life, and safety and tolerability measures

to assess bezisterim’s activity and clinical profile in early PD, with the goal of informing the design of a potentially pivotal

Phase 3 trial.

The trial successfully met prespecified endpoints and achieved its objectives,

with topline results showing that bezisterim improved blood based inflammatory markers of disease, along with a broad range of biological

markers associated with overall cellular health and nerve cell damage. Participants treated with bezisterim experienced greater improvements

than those receiving placebo across a series of clinical outcome measures of daily living, motor symptoms, and non-motor symptoms.

1 Movement Disorder Society-sponsored revision of the Unified Parkinson’s

Disease Rating Scale

“Topline results of the SUNRISE-PD trial are encouraging and demonstrate

the potential for bezisterim to address significant unmet clinical needs in Parkinson’s disease through a differentiated therapeutic

approach that targets the underlying disease biology, rather than focusing solely on symptomatic treatment provided by currently approved

therapies,” said Cuong Do, President and CEO of BioVie. “These exploratory results suggest that bezisterim may have the potential

to become the first drug candidate to improve clinical outcomes in Parkinson’s disease beyond motor symptoms. The findings also

indicate a potentially differentiated profile, with effects on underlying proteomic and biomarker endpoints, potential neurodegenerative

benefits, and improvements across both motor as well as non-motor clinical outcomes. Collectively, these results highlight bezisterim’s

potential to represent a meaningful advance in Parkinson’s disease treatment and provide a strong foundation for its continued clinical

development.”

The majority of patients treated with bezisterim showed improvement on

EPNIC-15,2 a composite endpoint encompassing 15 clinically relevant motor and non-motor measures of PD. In contrast, patients

receiving placebo showed a change in the opposite direction (bezisterim =

-0.04, placebo = +0.18, Cohen’s d = -0.94, p=0.0006). EPNIC-15 aligns clinical outcome measurements from UPDRS Parts I (non-motor

symptoms), II (activities of daily living), and III (motor symptoms), as well as PDSS-2 (sleep) with bezisterim’s proposed mechanism

of action, providing a sensitive tool to evaluate anti-inflammatory treatment effects in early PD.

While bezisterim appeared to demonstrate an effect across the trial population,

the greatest improvement was seen in those with higher levels of inflammation at baseline. Baseline platelet concentration, a biomarker

associated with inflammatory status, identified subgroups in which treatment effects were more pronounced, providing further support for

a potential role of inflammation in Parkinson’s disease.3 Among patients with baseline platelet counts >230 x103/µL,

who represent approximately one-half of the trial population, bezisterim treatment was associated with statistically significant advantages

over placebo across all clinical measures evaluated, including EPNIC-15 and MDS-UPDRS Parts I, II, and III, and MDS-UPDRS Total. These

findings provide a framework for patient selection for a future Phase 3 trial design.

2 The Early Parkinson’s Neuro-Inflammatory Composite 15 (EPNIC-15)

comprises 15 subdomains of UPDRS Part I (Sleep problems, Daytime sleepiness, Constipation), Part II (Hobbies/activities, Tremor (ADL),

Walking & balance), Part III (Speech, Toe tapping R, Toe tapping L, Leg agility L, Posture, Rest-tremor constancy), and PDSS-2 (Staying

asleep, Nocturia, Morning tired). It was constructed based on learnings from Biohaven/Broadstreet HEOR/Pentara in the creation of PARCOMS

(Parkinson's Composite Scale) (L'Italien et al. Neurology and Therapy 2025;14:1609–1625.)

3 Platelets reflect key aspects of neuronal pathology in Parkinson’s

disease, carrying α-synuclein and exhibiting mitochondrial Complex I deficits that parallel those observed in neurons (Chou et

al., Sci Rep 12, 14625 (2022). https://doi.org/10.1038/s41598-022-18992-1). In addition, platelet indices have been shown

to be causally associated with Parkinson’s disease independent of C-reactive protein (CRP) and other markers of classical systemic

inflammation (Wu et al., Cell Genomics, 2023), further supporting their potential utility as biomarkers of disease biology.

Platelet levels may help enrich future trials for PD patients more likely

to show a robust response rather than serving as a basis for excluding subgroups, as bezisterim’s treatment effects were observed

across the platelet spectrum.

“Improvement across both motor and non-motor domains of the MDS-UPDRS

is encouraging because these measures represent clinically meaningful outcomes recognized by physicians, patients, and the FDA,”

said Dr. Mark Stacy, William E. Murray Professor of Neurology at the Medical University of South Carolina. Dr. Stacy was formerly the

Vice Dean of Clinical Research at Duke University and has published over 200 manuscripts and the textbook Handbook of Dystonia.

“The finding that treatment effects were greater in patients with higher platelet levels supports the rationale that reduction in

neuronal inflammation remains an unmet need in neurodegenerative disease. It may also provide guidance for evaluating a more targeted

patient population in future studies.”

“Non-motor symptoms such as sleep disturbances, fatigue, and autonomic

dysfunction are consistently identified among the most burdensome and under-addressed concerns for people living with Parkinson’s

disease, a finding reinforced by our recent State of the Community Survey,” said James Beck, PhD, Chief Scientific Officer of the

Parkinson’s Foundation. “The results of this trial could represent a meaningful advancement in Parkinson's treatment and help

to address a significant unmet need in care.”

Bezisterim treatment was associated with statistically significant improvements

in several central and peripheral biomarkers of neuroinflammation (CCL2, CHI3L1, VGF) and systemic inflammation (including the monocyte-to-lymphocyte

ratio (MLR), the Systemic Inflammation Response Index (SIRI), and individual biomarkers such as CHI3L1, CCL2, IL-17A, IL-6, IFN-γ,

TNFα, others). The composite neuroinflammation measure was -0.28 in patients treated with bezisterim compared with +0.19 for placebo

(Cohen’s d = -1.06, p=0.0018), further supporting an effect of bezisterim on neuroinflammatory pathways.

Bezisterim treatment was associated with a broad, proteome-wide impact,

with 283 of 380 proteins shifting in the direction of a lower inflammatory burden (binomial p=3.2 X 10-22). This pattern is

directionally aligned with prior proteomic and inflammatory biomarker studies in Parkinson’s disease linking inflammatory protein

signatures with PD biology, clinical severity, and progression-related outcomes.4,5,6,7 Statistically significant improvements

were observed across central nervous system (CNS) and inflammatory biomarkers. Favorable changes were also observed in Aβ42 (p=0.0877)

and pTau-217 (p=0.1272). Collectively, these findings provide evidence of biological target engagement and suggest that bezisterim may

influence multiple pathways relevant to Parkinson’s disease.

4 Kaiser et al. npj Parkinson’s Disease. 2023;9:24.

doi:10.1038/s41531-023-00461-9.

5 Qu et al. npj Parkinson’s Disease. 2023;9:18. doi:10.1038/s41531-023-00449-5.

6 Hepp et al. International Journal of Molecular Sciences.

2023;24(19):14915. doi:10.3390/ijms241914915.

7 Chan et al. Aging. 2023;15(5):1603-1614. doi:10.18632/aging.204575.

Bezisterim treatment was associated with improvements from mid-study (week

4, V4) to end-of-study (week 12, V6) across a range of neurodegeneration biomarkers, including NfL, GFAP, UCHL1, BN02, and MAPT. The composite

neuronal injury signal decreased -0.09 for the bezisterim treatment group compared with an increase of +0.06 for placebo (Cohen’s

d = -0.57, p=0.043). NfL levels changed by -0.0148 log₂/week from V4 to V6 with bezisterim compared with +0.0095 log₂/week

with placebo (Cohen’s d = -0.746, p=0.008). These biomarker observations are exploratory in nature, and bezisterim’s potential

to influence underlying disease progression will require confirmation in future clinical trials.

Bezisterim was well tolerated and demonstrated a safety profile comparable

to placebo. The incidence of adverse events was similar between treatment groups (39.3% with bezisterim vs. 51.7% with placebo), with

no severe or serious adverse events and only one treatment-related adverse event reported in each group. Most adverse events were mild

in severity, while patients receiving placebo experienced a higher number of total adverse events and a greater proportion of moderate

adverse events than those treated with bezisterim.

“We are encouraged by the clinical, biomarker, proteomic, and safety

findings observed in this focused study of 57 patients over 12 weeks of treatment and look forward to presenting these results at an upcoming

medical meeting” said Joseph M. Palumbo, MD, Chief Medical Officer at BioVie. “These exploratory findings strengthen our confidence

in bezisterim’s potential to address the broad symptomatic burden of Parkinson’s disease and will inform the design of a future

potentially registration study.”

Conference call to discuss results

BioVie management will host a conference call at 4:15 p.m. EDT on August

12, 2026, to discuss the findings and results. A live Q&A session with management will follow the presentation.

To register for the conference call, please visit: https://www.redchip.com/webinar/BIVI/82597296515

Statistical Note

Unless otherwise noted, all p-values reported in this release are nominal

and unadjusted for multiplicity, consistent with the exploratory, signal-finding objectives of this Phase 2 study.

Selected Abbreviations

Aβ42: amyloid beta 42

AISI: aggregate index of systemic inflammation

GFAP: glial fibrillary acidic protein

IFN-γ: interferon gamma

MAPT: microtubule-associated protein tau

NfL: neurofilament light chain

NFκB: nuclear factor kappa B

NLR: neutrophil-to-lymphocyte ratio

PLR: platelet-to-lymphocyte ratio

SII: systemic immune-inflammation index

TNF-α: tumor necrosis factor alpha

UCHL1: ubiquitin carboxyl-terminal hydrolase L1

About Parkinson’s Disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder

worldwide, affecting more than 10 million people, including an estimated 1.1 million people in the United States, with nearly 90,000 new

diagnoses each year.8

PD is best known for motor symptoms such as tremor, rigidity, slowed movement,

and postural instability. However, PD involves neurodegeneration beyond the areas of the brain primarily associated with movement, giving

rise to a broad range of non-motor symptoms, including sleep disturbances, cognitive changes, depression, anxiety, fatigue and autonomic

dysfunction.9

Some non-motor symptoms may emerge years before a diagnosis of PD10

and can be more troublesome and disabling than movement symptoms.11 Non-motor symptoms are strongly associated with reduced

quality of life, yet they remain frequently under-recognized and undertreated.12˒13

8 Parkinson's Foundation. Statistics. Accessed July 16, 2026.

9 Peña-Zelayeta et al. J Pers Med. 2025;15(5):172.

doi:10.3390/jpm15050172.

10 Castilla-Cortázar et al. J Transl Med (2020) 18:70.

https://doi.org/10.1186/s12967-020-02223-0

11 Parkinson's Foundation. Non-movement symptoms. Accessed July 16,

2026.

12 van der Meer et al. Expert Rev Pharmacoecon Outcomes Res.

2025;25(1):17–27. doi:10.1080/14737167.2024.2390042.

13 Chaudhuri et al. Parkinsonism Relat Disord. 2015;21(3):287–291.

doi:10.1016/j.parkreldis.2014.12.031.

The economic burden of Parkinson's disease and atypical parkinsonism in

the United States was estimated at $82.2 billion in 2024, including $58.4 billion in indirect and non-medical costs, and is projected

to reach $112.4 billion annually by 2045.14 There remains a substantial need for treatments and care that address both the

motor and non-motor manifestations of PD.

About the SUNRISE-PD trial

SUNRISE-PD (NCT06757010) was

a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial designed to establish proof-of-mechanism and proof-of-concept

in early-stage Parkinson’s disease (PD) patients naïve to treatment with symptomatic dopaminergic therapy (carbidopa/levodopa).

The study leveraged a hybrid decentralized design that lasted 20 weeks from the initial screening phase, a 12-week treatment period, through

to the safety follow up.

Following a screening and prospective clinical stability assessment period,

57 eligible participants were randomized 1:1 to receive either 20 mg of bezisterim or matching placebo twice daily for 12 weeks.

The study prospectively evaluated a predefined battery of biologic, clinical,

and quality of life assessments to assess a series of motor and non-motor endpoints and evaluate signals consistent with bezisterim’s

expected metabolic and anti-inflammatory actions. The trial endpoints and planned analyses were prespecified in the final Statistical

Analysis Plan (SAP) submitted to the FDA prior to data unblinding.

The primary pharmacodynamic endpoint was to assess the effect of bezisterim

on hematologic inflammatory biomarker indices (MLR, SIRI, NLR, SII, PLR, AISI) and a composite of those markers. Secondary and exploratory

endpoints aimed to understand the pharmacodynamic, clinical, safety and tolerability, and to define the profile of bezisterim versus placebo

in the study population to design a potentially pivotal registrational Phase 3 trial.

14 The Lewin Group. Economic burden of Parkinson's and atypical parkinsonism

in the United States: full study report. Prepared for The Michael J. Fox Foundation for Parkinson's Research; February 17, 2026.

The study was designed to reduce common barriers to participation in PD

research, including delayed diagnosis, limited mobility, geographic constraints, and access to specialized care, and allowed patients

to participate either from their home or at a clinical site. At-home participants were visited by study nurses who administered a modified

MDS-UPDRS Part III and standard Part I and II examinations under the supervision of a physician and MDS-UPDRS expert attending through

live video link. The Part III exam was recorded for review and scoring by a central rating committee with a final expert rater review

and adjudication.

About Bezisterim

Bezisterim (NE3107) is an investigational oral drug that crosses the blood-brain

barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of

drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNFα), bezisterim may have therapeutic

potential in several disease indications, including Parkinson’s disease (PD), Long COVID (LC), and Alzheimer’s disease (AD).

In PD, BioVie previously completed a Phase 2 study in which patients with

moderate- to severe-stage PD taking bezisterim with levodopa had better motor control and reported fewer morning symptoms compared to

those taking levodopa alone. Few drug-related side effects were observed. The current SUNRISE-PD study aimed to establish proof-of-mechanism

and proof-of-concept in patients with early-stage PD who had not previously been treated with carbidopa/levodopa.

For LC, the ADDRESS-LC trial is enrolling approximately 200 patients to

evaluate whether bezisterim may help reduce brain fog, fatigue, and other lingering neurological symptoms associated with LC. The hypothesis

being studied is that these symptoms may be triggered by persistent circulation of spike protein fragments that trigger inflammation via

NFκB activation (which bezisterim has been shown to modulate). Topline data is expected late summer 2026.

In AD, BioVie has conducted Phase 2 and Phase 3 trials. Preliminary data

from these trials suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for

the six million Americans living with AD.

About BioVie Inc.

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company

focused on developing therapies for neurological disorders and advanced liver disease. Its lead investigational drug candidate, bezisterim

(NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s

disease. Bezisterim is also being studied for Long COVID, where persistent inflammation is thought to underlie symptoms such as brain

fog and fatigue.

In liver disease, BioVie is advancing BIV201, a continuous infusion of

terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about

40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction

of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, which may be identified

by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe,"

"seek," "estimate," "will," "project," “potential,” “may,” or words of

similar meaning. Forward-looking statements in this release include, but are not limited to, statements regarding: the potential for bezisterim

to address unmet clinical needs in Parkinson’s disease; the design and conduct of future clinical trials, including a potentially

pivotal Phase 3 trial; the potential clinical significance of biomarker and proteomic observations; and the Company’s ability to

advance bezisterim through clinical development. The biomarker and proteomic endpoints reported in this release are exploratory in nature.

Changes in such biomarkers may not correlate with clinical benefit or support regulatory approval. The FDA has not validated these biomarkers

as surrogate endpoints for Parkinson’s disease. Although BioVie Inc. believes such forward-looking statements are based on reasonable

assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed

or implied by the statements herein due to risks related to the early stage of development of bezisterim and other product candidates,

the possibility that results observed in this Phase 2 study of 57 patients over 12 weeks may not be replicated in larger or longer-duration

trials, the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual

and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical

studies and to obtain approval for our product candidates, the possibility that clinical trial results may not be indicative of results

in subsequent or larger trials, our ability to successfully defend potential future litigation, changes in local or national economic

conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are

detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K

and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking

statements), except as required by law.

For Investor Relations Inquiries:

Contact:

Chuck Padala

Managing Director, LifeSci Advisors, LLC

chuck@lifesciadvisors.com

For Media Inquiries:

Contact:

Melyssa Weible

Managing Partner, Elixir Health Public Relations

mweible@elixirhealthpr.com

GRAPHIC

Filename: image_01.jpg · Sequence: 7

Binary file (108874 bytes)

Download image_01.jpg

GRAPHIC

Filename: image_02.jpg · Sequence: 8

Binary file (86171 bytes)

Download image_02.jpg

GRAPHIC

Filename: image_03.jpg · Sequence: 9

Binary file (158911 bytes)

Download image_03.jpg

GRAPHIC

Filename: image_04.jpg · Sequence: 10

Binary file (118233 bytes)

Download image_04.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 12

v3.26.1

Cover

Aug. 06, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 06, 2026

Entity File Number

001-39015

Entity Registrant Name

BioVie Inc.

Entity Central Index Key

0001580149

Entity Tax Identification Number

46-2510769

Entity Incorporation, State or Country Code

Entity Address, Address Line One

680 W Nye Lane

Entity Address, Address Line Two

Suite 201

Entity Address, City or Town

Carson City

Entity Address, State or Province

Entity Address, Postal Zip Code

89703

City Area Code

775

Local Phone Number

888-3162

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Class A Common Stock, Par Value $0.0001 Per Share

Title of 12(b) Security

Class A Common Stock, Par Value $0.0001 Per Share

Trading Symbol

BIVI

Security Exchange Name

NASDAQ

Warrants to purchase Class A Common Stock, $0.0001 par value per share

Title of 12(b) Security

Warrants to purchase Class A Common Stock, $0.0001 par value per share

Trading Symbol

BIVIW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=bivi_ClassCommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=bivi_WarrantsToPurchaseClassCommonStock0.0001ParValuePerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: